

**CLAIMS**

1. Use of a mutant C-C chemokine chosen amongst RANTES, MIP-1alpha, MIP-1beta and their muteins having at least 90% homology with the corresponding wild-type (WT) molecule, to produce a pharmaceutical composition for treating or preventing autoimmune and inflammatory diseases, as well as bacterial and viral infections by oral administration, wherein said mutant comprises at least one non-conservative mutation in the 40's dibasic site.
2. The use according to claim 1 wherein the muteins have from 95% to 99% of homology with the corresponding WT molecule.
3. The use according to claim 1 or 2 wherein the mutant contains Alanine or Glutamic Acid in at least one of the positions of the 40's dibasic site.
4. The use according to any preceding claim wherein the muteins comprise an amino acid sequence selected from the group consisting of SEQ ID Nos: 1, 2, 3, 4, 5, 6, 7, 8 and 9.
5. The use according to any preceding claims wherein the mutein has the amino acid sequence of SEQ ID NO: 1 and the autoimmune disease is multiple sclerosis.